Yes, removal of the prostate can cause impotence, but it does not inevitably do so. Radical prostatectomy damages erection through several distinct mechanisms, and the odds of preserving function depend heavily on nerve-sparing technique, baseline function, age, and which definition of impotence you use. Modern series show roughly half to three-quarters of previously potent men recover erections sufficient for intercourse within two years, with wide variation across surgeons and risk groups (EAU Guidelines on Prostate Cancer, 2023).
The prostate sits at the crossroads of the urinary and reproductive tracts, wrapped by a thin web of autonomic nerves that control blood flow into the penis. Surgery removes the gland, the seminal vesicles, and often nearby tissue. What happens to those nerves, and to the arteries and smooth muscle they regulate, determines whether erections return and how completely.
The erectile mechanism and what surgery disrupts
An erection is a hydraulic event. Parasympathetic fibers from the pelvic splanchnic nerves release nitric oxide into the cavernous arteries and the trabecular smooth muscle of the corpora cavernosa. Nitric oxide triggers cyclic guanosine monophosphate signaling, the smooth muscle relaxes, and arterial inflow outpaces venous outflow. Blood traps in the penis and pressure rises.
Those parasympathetic fibers run in the neurovascular bundles, two ribbon-like structures that hug the posterolateral prostate between the gland and the rectum. They originate from the pelvic plexus and travel within centimeters of the prostatic capsule. The bundles are small, fragile, and not always symmetrical; cadaver and intraoperative studies show accessory or aberrant courses in a meaningful minority of men.
Radical prostatectomy removes the prostate and seminal vesicles. To clear oncologic margins, the surgeon must dissect along the capsule, which places the bundles at risk from traction, thermal injury during cautery, partial or complete transection, and local inflammation. Even when a bundle is anatomically preserved, the nerve fibers inside it can be stretched or devascularized. That is why "nerve-sparing" describes a surgical intent and a visible plane, not a guaranteed physiological result.
Erection also depends on arterial inflow through the internal pudendal arteries and on the veno-occlusive mechanism inside the corpora. Surgery can compromise accessory pudendal arteries that cross near the prostate in some men, and postoperative fibrosis and smooth muscle hypoxia can degrade the trapping mechanism even if nerves survive. The result is often a mixed vasculogenic and neurogenic erectile dysfunction rather than a pure nerve injury.
A short way to hold this: the operation removes a gland, but the erection hinges on nerves, arteries, and tissue health that run beside and beyond it.
Quantified context: how often, and by when
Precise figures vary because studies differ in definitions, follow-up, and patient mix. Broad, replicated patterns hold. Bilateral nerve-sparing surgery in potent men under about 60, performed by high-volume surgeons, yields the best recovery. Non-nerve-sparing surgery in older men or those with poor baseline function yields the worst. Population statistics are less useful than your own risk profile, but the ranges orient you.
| Scenario | Approximate potency recovery within 1 to 2 years | Key caveat |
|---|---|---|
| Bilateral nerve-sparing, age under 60, potent preoperatively | Roughly 60-85% | Surgeon volume and technique dominate |
| Unilateral nerve-sparing | Roughly 40-60% | Depends heavily on the preserved side |
| Non-nerve-sparing | Roughly 10-30% | Higher risk with extraprostatic extension |
| Men over 70 regardless of approach | Lower and slower | Baseline function already reduced |
| Salvage surgery after radiation | Markedly lower | Tissue planes obscured by fibrosis |
| Robotic versus open, high-volume surgeons | Broadly similar | Technique matters more than platform |
The ranges are wide because "potency" is not one thing. Some studies score it as any erection sufficient for intercourse, others as rigid enough for penetration without aid, and others by validated questionnaire domains. A man who recovers with a phosphodiesterase type 5 inhibitor counts as potent in some series and not in others. That definitional slack alone can swing reported rates by tens of percentage points.
Time course matters as much as the endpoint. Recovery is not a switch.
| Postoperative interval | Typical status | What is happening biologically |
|---|---|---|
| 0-2 weeks | Catheter in place; no erections expected | Acute surgical trauma and swelling |
| 2-6 weeks | Few or no spontaneous erections | Nerve stunning, pain, anxiety |
| 6 weeks-3 months | Partial or weak erections may begin | Early nerve recovery, tissue hypoxia risk |
| 3-6 months | Variable, often partial | Smooth muscle and nerve regeneration |
| 6-12 months | Continued improvement in many men | Remodeling of cavernosal tissue |
| 12-24 months | Plateau for most; late gains possible | Fibrosis versus recovery balance |
| Beyond 24 months | Stable in most; small late-improvement tail | Residual nerve function may still emerge |
The practical implication: judging outcome at three months is premature, and waiting two years before seeking help wastes the window when penile tissue is most salvageable.
Edge cases that change the calculus
Several situations bend the general rules.
Cancer that extends beyond the capsule, or sits at the apex or bladder neck, forces wider excision. A surgeon may intentionally resect a neurovascular bundle to achieve a negative margin. In that trade-off, cancer control wins, and the man should understand before surgery which side is at risk. Preoperative MRI and nomograms can estimate extraprostatic extension but not perfectly.
Age and baseline function interact. A 68-year-old with marginal erections before surgery has less reserve, so even good nerve-sparing may leave him dependent on medication. A 55-year-old with robust function has more to lose in absolute terms but also more capacity to recover.
Salvage prostatectomy after failed radiation is a distinct operation. Radiation fibrosis obliterates the planes around the bundles, and potency outcomes are substantially worse. Focal therapies such as high-intensity focused ultrasound or cryotherapy spare nerves less reliably than textbooks imply, and their erectile outcomes are not uniformly superior to surgery.
Surgeon volume and case selection are underappreciated variables. Outcomes cluster by surgeon and by center, and a high-volume surgeon's personal series can look far better than a pooled average. That is a legitimate reason to ask about a specific surgeon's own potency data rather than relying on general statistics.
A counterintuitive professional caveat: a man may report satisfactory erections yet have measurable penile shortening or a mild venous leak that only shows up under stress. Conversely, some men with objectively reduced rigidity adapt well and do not consider themselves impotent. Patient-reported outcomes and laboratory measures diverge, so both matter.
Misconceptions worth correcting
Nerve-sparing does not mean nerve preservation is guaranteed. It means the surgeon identified and tried to preserve the bundle. Fibers within the bundle can still be injured by traction and heat.
Impotence is not necessarily permanent. Many men recover partial or full function over 12 to 24 months, especially with early rehabilitation and vascular protection.
Erection recovery is not just about nerves. Arterial inflow, cavernosal smooth muscle health, and venous competence all contribute, which is why diabetes, smoking, and hypertension worsen outcomes.
Robotic surgery is not automatically superior for potency. High-quality comparisons suggest outcomes depend more on surgeon skill and patient selection than on the robot itself.
Waiting to see what happens is not neutral. Without erections or proactive therapy, cavernosal tissue undergoes hypoxia-driven fibrosis, which can convert a recoverable nerve injury into permanent structural dysfunction.
Red-flag warnings to raise before surgery: A surgeon who cannot describe their own potency outcomes or nerve-sparing rates. Baseline erections already poor, with no plan discussed for penile rehabilitation. Cancer features suggesting bundle resection, with no explicit conversation about the trade-off. No discussion of arterial risk factors such as diabetes, smoking, or hypertension. No plan for early erectile rehabilitation in the first months after surgery.
Practical actions and thresholds
These are general educational steps, not a treatment plan; decisions belong with your care team.
Ask for your surgeon's own data. Request potency recovery rates stratified by nerve-sparing status and age, not just a general figure.
Know your baseline. Before surgery, document erectile function with a validated instrument such as the International Index of Erectile Function, and note morning erections. This creates the comparison point.
Start rehabilitation early. Many centers begin erectile rehabilitation within weeks of catheter removal, using vacuum erection devices, phosphodiesterase type 5 inhibitors, or both, to maintain tissue oxygenation. Ask what protocol your surgeon uses and why.
Control vascular risk factors before and after surgery. Optimize blood pressure, blood sugar, and smoking cessation; these affect both recovery and long-term function.
Seek help by six months if no erections have returned. Persistent absence of any erection by that point warrants evaluation for secondary causes and consideration of more aggressive therapy.
Track recovery on a timeline. Reassess at 3, 6, 12, and 24 months rather than at a single early visit.
Limitations of the evidence
Potency outcomes are hard to compare across studies. Definitions vary, follow-up differs, and surgeon skill is not captured in most datasets. Many series come from high-volume centers and may overstate typical results. Randomized trials comparing surgical techniques for potency are few, and most evidence is observational.
Erection recovery also depends on factors trials rarely measure: partner support, anxiety, relationship context, and adherence to rehabilitation. Those are real influences but hard to quantify.
What can be said with confidence is directional: nerve-sparing helps, younger potent men do better, time and rehabilitation matter, and permanent impotence is a risk rather than a certainty. What cannot be said with confidence is a precise number for any individual man. That number depends on his anatomy, his cancer, and his surgeon's hands, and it is best estimated by asking for local outcomes rather than trusting a pooled average.